bluebird bio Sells Second Priority Review Voucher for $95 M

 Non-dilutive capital further strengthens Company’s financial position –

 

 bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into a definitive agreement to sell its second Rare Pediatric Disease Priority Review Voucher (PRV) for $95 million.

bluebird bio was granted two PRVs upon the US Food and Drug Administration (FDA) approvals of ZYNTEGLO® (betibeglogene autotemcel) for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusions and SKYSONA® (elivaldogene autotemcel) for the treatment of early, active cerebral adrenoleukodystrophy, on August 17, 2022 and September 16, 2022 respectively. On December 29, 2022, bluebird closed the sale of its first PRV for $102 million.

“The sale of our second priority review voucher further bolsters our financial position and provides an important source of non-dilutive funding for the company,” said Chris Krawtschuk, chief financial officer, bluebird bio. “Strengthening the company’s balance sheet – as we have continued to do through demonstrated fiscal discipline and the sale of both PRVs – ensures we enter 2023 with significant momentum behind the commercial launches of our two FDA-approved gene therapies, and the opportunity ahead in sickle cell disease.”

bluebird received a payment of $95 million upon closing of the transaction, which occurred simultaneously with the parties entering into the agreement. Jefferies LLC acted as the exclusive financial advisor to bluebird for this transaction.

https://www.biospace.com/article/releases/bluebird-bio-sells-second-priority-review-voucher-for-95-million/